Zobrazeno 1 - 10
of 60
pro vyhledávání: '"Steven G. DuBois"'
Autor:
Alanna J. Church, Laura B. Corson, Pei-Chi Kao, Alma Imamovic-Tuco, Deirdre Reidy, Duong Doan, Wenjun Kang, Navin Pinto, Luke Maese, Theodore W. Laetsch, AeRang Kim, Susan I. Colace, Margaret E. Macy, Mark A. Applebaum, Rochelle Bagatell, Amit J. Sabnis, Daniel A. Weiser, Julia L. Glade-Bender, Alan C. Homans, John Hipps, Haley Harris, Danielle Manning, Alyaa Al-Ibraheemi, Yvonne Li, Hersh Gupta, Andrew D. Cherniack, Ying-Chun Lo, Gianna R. Strand, Lobin A. Lee, R. Seth Pinches, Lorena Lazo De La Vega, Maegan V. Harden, Niall J. Lennon, Seong Choi, Hannah Comeau, Marian H. Harris, Suzanne J. Forrest, Catherine M. Clinton, Brian D. Crompton, Junne Kamihara, Laura E. MacConaill, Samuel L. Volchenboum, Neal I. Lindeman, Eliezer Van Allen, Steven G. DuBois, Wendy B. London, Katherine A. Janeway
Publikováno v:
Nature Medicine. 28:1581-1589
To evaluate the clinical impact of molecular tumor profiling (MTP) with targeted sequencing panel tests, pediatric patients with extracranial solid tumors were enrolled in a prospective observational cohort study at 12 institutions. In the 345-patien
Autor:
Benjamin Mizukawa, Vanessa A Fabrizio, Neerav Shukla, Sharon M. Castellino, Daniel S. Wechsler, Marilyn Winchester, Nancy Bouvier, Ahmet Zehir, Brian Turpin, David S. Shulman, Himalee S. Sabnis, Jason Fangusaro, Julia Glade-Bender, Steven G. DuBois, Chanta Whitlow, Laura Agresta
Publikováno v:
J Clin Oncol
PURPOSE The US Food and Drug Administration–expanded access program (EAP) uses a single patient use (SPU) mechanism to provide patient access to investigational agents in situations where no satisfactory or comparable therapy is available. Genomic
Autor:
Kieuhoa T. Vo, Steven G. DuBois, John Neuhaus, Steve E. Braunstein, Brent R. Weil, Arlene Naranjo, Sabine Irtan, Julia Balaguer, Katherine K. Matthay
Publikováno v:
PEDIATRIC BLOOD & CANCER
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
We sought to analyze biologic, clinical, and prognostic differences according to pattern of failure at the time of first relapse in neuroblastoma.Children21 years diagnosed with neuroblastoma between 1989 and 2017 with known site of first relapse (is
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::90c7668f3288e89c10c03ee71bac9136
https://fundanet.iislafe.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=15562
https://fundanet.iislafe.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=15562
Autor:
Jaclyn Schienda, Alanna J. Church, Laura B. Corson, Brennan Decker, Catherine M. Clinton, Danielle K. Manning, Alma Imamovic-Tuco, Deirdre Reidy, Gianna R. Strand, Mark A. Applebaum, Rochelle Bagatell, Steven G. DuBois, Julia L. Glade-Bender, Wenjun Kang, AeRang Kim, Theodore W. Laetsch, Margaret E. Macy, Luke Maese, Navin Pinto, Amit J. Sabnis, Joshua D. Schiffman, Susan I. Colace, Samuel L. Volchenboum, Daniel A. Weiser, Jonathan A. Nowak, Neal I. Lindeman, Katherine A. Janeway, Brian D. Crompton, Junne Kamihara
Publikováno v:
JCO Precision Oncology
PURPOSE Molecular tumor profiling is becoming a routine part of clinical cancer care, typically involving tumor-only panel testing without matched germline. We hypothesized that integrated germline sequencing could improve clinical interpretation and
Autor:
Mark Krailo, Douglas S. Hawkins, Katherine A. Janeway, Steven G. DuBois, Patrick J. Leavey, Allen Buxton, Paul J. Chuba, Richard B. Womer, Nadia N. Laack, Leo Mascarenhas, Helen Nadel, Daniel J. Indelicato, Neyssa Marina, Dian Wang, Atif A. Ahmed, Damon R. Reed, Ken Brown, Bruce R. Pawel, Mark L. Bernstein, R. Lor Randall, Holcombe E. Grier, Richard Gorlick, G. Douglas Letson, Alexis Maciej
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol 39, iss 36
J Clin Oncol
J Clin Oncol
PURPOSE The primary aim of this phase III randomized trial was to test whether the addition of vincristine, topotecan, and cyclophosphamide (VTC) to interval compressed chemotherapy improved survival outcomes for patients with previously untreated no
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eabada51e1a7145dd6bead1da83d3d8e
https://escholarship.org/uc/item/83q6v33g
https://escholarship.org/uc/item/83q6v33g
Autor:
Julie R. Park, Kevin Campbell, Rochelle Bagatell, Arlene Naranjo, Steven G. DuBois, Julie M. Gastier-Foster, Hiroyuki Shimada, Emily Hibbitts, Michael D. Hogarty, Meredith S. Irwin
Publikováno v:
Eur J Cancer
PURPOSE: MYCN amplification (MNA) is associated with poor outcomes in neuroblastoma. Less is known about heterogeneous MNA within a tumor. We compared clinical characteristics, biologic features, and clinical outcomes of patients with heterogeneous M
Autor:
Alberto S. Pappo, Makoto Tahara, Russell J. Schilder, Theodore W. Laetsch, Ray McDermott, Barrett H. Childs, Cornelis M. van Tilburg, Jyoti D. Patel, Shivaani Kummar, Catherine M. Albert, Olaf Witt, Shivani Nanda, Alexander Drilon, Anna F. Farago, Birgit Geoerger, Erin R. Rudzinski, Marc Ladanyi, Ramamoorthy Nagasubramanian, Steven G. DuBois, Stefan M. Pfister, Kristoffer Staal Rohrberg, Leo Mascarenhas, David M. Hyman, Jordan Berlin, Stefan S. Bielack, David S. Hong, Afshin Dowlati, François Doz, Noah Federman
Publikováno v:
The Lancet. Oncology, vol 21, iss 4
BackgroundThe selective TRK inhibitor larotrectinib was approved for paediatric and adult patients with advanced TRK fusion-positive solid tumours based on a primary analysis set of 55 patients. The aim of our analysis was to explore the efficacy and
Autor:
Yael P. Mosse, Brian Weiss, Fariba Goodarzian, Navin Pinto, Judith G. Villablanca, Gregory A. Yanik, Scarlett Czarnecki, Suzanne Shusterman, Araz Marachelian, Anasheh Shamirian, Hiroyuki Shimada, Rachel Berkovich, John M. Maris, Daphne A. Haas-Kogan, Julie R. Park, M. Meaghan Granger, Clare J. Twist, Steven G. DuBois, Lingyun Ji, Kieuhoa T. Vo, Susan L. Cohn, Katherine K. Matthay, Denice D. Tsao-Wei, Kelly C. Goldsmith, Susan Groshen, Meredith S. Irwin
Publikováno v:
J Clin Oncol
PURPOSE 131I-metaiodobenzylguanidine (MIBG) is an active radiotherapeutic for neuroblastoma. The primary aim of this trial was to identify which of three MIBG regimens was likely associated with the highest true response rate. PATIENTS AND METHODS Pa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f5465588083dc929da824e7729c79092
https://europepmc.org/articles/PMC8547934/
https://europepmc.org/articles/PMC8547934/
Autor:
Rochelle Bagatell, Steven G. DuBois
Publikováno v:
J Clin Oncol
Induction therapy is a critical component of the therapy of high-risk neuroblastoma. We aimed to assess if the Memorial Sloan Kettering Cancer Center (MSKCC) N5 induction regimen (MSKCC-N5) would improve metastatic complete response (mCR) rate and 3-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cb72a9c4e44e7001b44bf2e08f1c614a
https://europepmc.org/articles/PMC8330963/
https://europepmc.org/articles/PMC8330963/
Autor:
Emily Hibbitts, Julie R. Park, M. Meaghan Granger, Rochelle Bagatell, Navin Pinto, Susan G. Kreissman, Meredith S. Irwin, Wendy B. London, Arlene Naranjo, Emily Greengard, Steven G. DuBois
Publikováno v:
Eur J Cancer
Induction chemotherapy plays an important role in the management of patients with high-risk neuroblastoma. Predictors of response to induction therapy are largely lacking. We sought to describe clinical and biological features associated with inducti